Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2024 · $2,000,000
Apr 1, 2024 – Mar 31, 2027
Solicitation PA23-230 (2023) · Topic 44
Discovery of antiviral inhibitors for the treatment of orthopoxvirus infections
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2023 · $600,000
Jul 24, 2023 – Jun 30, 2025
Solicitation PA22-176 (2022) · Topic R43
Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2023 · $2,999,998
Jun 7, 2023 – May 31, 2026
Solicitation PA22-176 (2022) · Topic NIAID
Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2022 · $3,000,000
Mar 10, 2022 – Feb 28, 2025
Solicitation PA21-259 (2021) · Topic NIAID
Preclinical development of capsid assembly modulators for the treatment of chronic hepatitis B virus infection
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2021 · $3,000,000
May 24, 2021 – Apr 30, 2024
Solicitation PA20-260 (2020) · Topic R
Discovery of inhibitors that target HBx for the treatment of chronic HBV infection
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2021 · $506,623
Dec 15, 2020 – Nov 30, 2022
Solicitation PA19-272 (2019) · Topic R
Discovery of antiviral inhibitors of Ebola virus replication
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2020 · $600,000
Jul 15, 2020 – Jun 30, 2022
Solicitation PA19-272 (2019) · Topic NIAID
Advancement of antiviral inhibitors of chikungunya virus
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2019 · $3,000,000
May 15, 2019 – Apr 30, 2022
Solicitation PA18-574 (2018) · Topic NIAID
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2018 · $3,000,000
Feb 7, 2018 – Jan 31, 2021
Solicitation PA17-302 (2017) · Topic NIAID
Advancement to IND of novel BLI for pairing with cefixime
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2017 · $3,000,000
Aug 7, 2017 – Jul 31, 2020
Solicitation PA16-302 (2016) · Topic NIAID
Discovery of inhibitors of Zika virus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2017 · $599,998
Mar 15, 2017 – Feb 28, 2019
Solicitation PA15-269 (2015) · Topic NIAID
Advancement to Clinical Candidate of Novel, Potent and Selective Chikungunya virus inhibitor series
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2016 · $3,462,890
Jul 5, 2016 – Jun 30, 2019
Solicitation PAR14-088 (2014) · Topic NIAID
Discovery of inhibitors of BK polyomavirus
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2016 · $690,598
Jul 2, 2016 – Jun 30, 2018
Solicitation PA15-269 (2015) · Topic NIAID
Novel Combination Product with Activity Against MRSA, MDR-Enterics and Pseudomonas
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $600,000
Jun 15, 2015 – May 31, 2017
Solicitation PA14-071 (2015) · Topic R
Discovery and Advancement of Chikungunya virus inhibitors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2015 · $600,000
Mar 1, 2015 – Feb 28, 2017
Solicitation PA14-071 (2015) · Topic NIAID
Broad-spectrum, orally-bioavailable beta-lactamase inhibitors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2014 · $599,200
Jun 1, 2014 – May 31, 2016
Solicitation PA10-123 (2015) · Topic R
Phase II SBIR: Responding to NDM-1 - Advancement of a new MBL inhibitor to IND
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $3,000,000
Sep 1, 2013 – Aug 31, 2016
Solicitation PA10-123 (2013) · Topic NIAID
Preserving beta-lactam utility vs pathogens producing any class of beta-lactamase
SBIR Phase II · Department of Health and Human Services (National Institutes of Health) · 2013 · $3,000,000
Aug 1, 2013 – Jul 31, 2016
Solicitation PA10-123 (2013) · Topic NIAID
Novel Compounds Targeting Bacterial PBPs
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2012 · $600,000
Solicitation PA10-123 (2012) · Topic NIAID · Research partner: Stub
Novel Metallo-beta-lactamase Inhibitors
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $600,000
Solicitation PA10-123 (2011) · Topic NIAID · Research partner: Stub
Preserving beta-lactam utility against pathogens producing all classes of beta-la
SBIR Phase I · Department of Health and Human Services (National Institutes of Health) · 2011 · $600,000
Solicitation PA10-123 (2011) · Topic NIAID · Research partner: Stub
